In vitro activity of lomefloxacin (SC 47111 or NY-198) against isolates of Legionella spp.
The in vitro activity of lomefloxacin (SC-47111 or NY-198) was compared with those of erythromycin and rifampin against a total of 180 Legionella spp. strains isolated from nosocomial or acquired respiratory tract infections and from environmental sources. Rifampin was the most active agent tested (MIC90, 0.008 microgram/ml) against Legionella spp. However, lomefloxacin was found 2-to-4-fold more active than erythromycin against most Legionella strains tested. Against Legionella pneumophila, lomefloxacin (MIC90, 0.12 microgram/ml) was significantly more than erythromycin (MIC90, 0.5 micrograms/ml). L. pneumophila serogroup 2, 3, and 5 strains (MIC90, 0.06 micrograms/ml) were more susceptible than L. pneumophila serogroup 1, 4, 6, 7, and 8 (MIC90, 0.12 microgram/ml). L. dumoffii was the most resistant species with a MIC90 of 0.25 microgram/ml and 0.5 microgram/ml, respectively, to lomefloxacin and erythromycin. The activity of lomefloxacin was similar against the isolates obtained from patients or from environmental sources.
Dubois
J
J
Centre Hospitalier Hôtel-Dieu de Sherbrooke, Québec, Canada.
Joly
J R
JR
D042462:4-Quinolones; D000890:Anti-Infective Agents / Q000494:pharmacology*; D003428:Cross Infection / Q000175:diagnosis; D004917:Erythromycin / Q000494:pharmacology; D024841:Fluoroquinolones; D006801:Humans; D007875:Legionella / Q000187:drug effects* / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D015363:Quinolones; D012120:Respiration Disorders / Q000175:diagnosis / Q000382:microbiology; D012293:Rifampin / Q000494:pharmacology
D042462:4-Quinolones; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D004917:Erythromycin; C053091:lomefloxacin; D012293:Rifampin